Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China

Phase 1

Completed

• Conditions: HCV
• Interventions: Drug: Danoprevir; Drug: Placebo; Drug: Ritonavir; Drug: Ravidasvir

• Registration Number: NCT03288636
• Lead Sponsor: Ascletis Pharmaceuticals Co., Ltd.

Brief Summary

The purpose of this study is to investigate the Pharmacokinetics and Safety of single dose of Ravidasvir and Danoprevir/r and repeated doses of Ravidasvir in combination with Danoprevir/r in healthy volunteers.

Detailed Description

Not available

Study Timeline

• Study Start: 2017-08-08
• Study First Submitted: 2017-08-09
• Primary Completion: 2017-09-14
• Study First Submitted QC: 2017-09-19
• Study First Posted: 2017-09-20
• Status Verified: 2017-10
• Study Completion: 2017-10-28
• Last Update Submitted: 2018-01-14
• Last Update Posted: 2018-01-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 18

Inclusion Criteria

• Age between 18-45 years old;
• Male body weight not less than 50kg; Female body weight not less than 45kg; BMI in the range of 19~28kg/m2
• Healthy men or women based on history, physical examination, laboratory examination and ECG.
• Female subjects should be surgically sterilized (bilateral tubal ligation, bilateral ovariectomy or hysterectomy); or are willing to use at least one of the following contraceptive methods within 30 days of the first administration of the study drug until the last administration: I Male partner vas deferens ligation; II. Non-hormonal contraceptive methods: intrauterine contraceptives, condoms, contraceptive sponges, septa, vaginal ring containing sizing gel or cream.
• Male subjects should be surgically sterilized; or are willing to use at least one of the following contraceptive methods within 30 days from the first administration of the study to the last administration: I. Female partners abstinence during the study period (including no donation): II. Compounds use hormonal contraceptives (oral, vaginal, parenteral or transdermal); III. Subjects and / or their female partners use non-hormonal contraceptive methods: condoms, contraceptive sponges, membranes, intrauterine devices, Fine gel or cream of the vaginal ring.
• If female, the pregnancy test result should be negative during the screening period.
• Voluntary to sign the informed consent.

Exclusion Criteria

• History or presence of cardiovascular disease, respiratory disease, endocrine and metabolic system disease, urinary system, digestive system, hematological system diseases, nervous system or Psychiatric diseases, and acute or chronic infectious disease and malignant tumor.
• A history of drug or food allergy.
• Positive test in any of the HBsAg、HCV Ab、HIV Ab and Syphilis Ab.
• Any of the AST、ALT、ALP、TBIL and DBIL exceed the upper limits of normal, or other laboratory test results exceeding the normal range and judged by the investigator to be clinically significant.
• History of gastrointestinal surgery, trunk vagotomy, intestinal excision or any other surgeries that could disturb gastrointestinal motility and PH absorption.
• Female who were during pregnancy, breastfeeding, period and unwilling to take reliable birth control method.
• Female partners were fertile and unwilling to take reliable contraceptive measures.
• Others as specified in the detailed protocol.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Experimental	Danoprevir	PKGroup: Ravidasvir + Danoprevir/ Ritonavir
Placebo	Placebo	Placebo Group: Placebo
Experimental	Ritonavir	PKGroup: Ravidasvir + Danoprevir/ Ritonavir
Experimental	Ravidasvir	PKGroup: Ravidasvir + Danoprevir/ Ritonavir

Primary Outcome Measures

Name	Time	Method
Incidence of adverse events	40 days	Incidence of adverse events

Trial Locations

Locations (1)

The first hospital of Zhejiang province; 🇨🇳 Hangzhou, Zhejiang, China